Business Wire

Dole Food Company Releases 2020 Corporate Responsibility & Sustainability Report

Share

Dole Food Company announced today the release of its 2020 Corporate Responsibility & Sustainability Report. The report unveils the organization’s new sustainability framework, “The Dole Way,” along with the company’s first-ever enterprise-wide sustainability goals.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200422005205/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Dole Fresh Fruit, Pineapple Farm (Photo: Business Wire)

“Since our founding, Dole has strived to deliver the best of which we are capable—in both our products and how we produce them,” stated Johan Linden, CEO of Dole. “The need for healthy food choices has never been more evident than during these past weeks as we adapt under this global pandemic. The journey and dedication to be a responsible citizen of our communities as well as a good steward of our land will continue into our future and Dole will remain steadfast in being honest and transparent about our efforts and our impacts in supplying wholesome food across the globe.”

“Of course,” Linden continued, “our stakeholders expect this of us, but even more we expect this of ourselves; to engage in open dialogue, including critical voices, to make a measurable and meaningful difference for people and the planet, and to constantly evaluate and improve. It’s what we believe is the right way to do business.”

Dole’s sustainability report outlines an ambitious slate of initiatives under the Dole Way framework focused on tangible action directed towards five key goals:

  • More than ever, Dole understands our responsibility to positively impact underserved communities and promises to donate no less that 2,500 tons of fresh fruit and produce by 2025.
  • Dole will effect valuable long-term change by declaring a social premium for Dole branded bananas and pineapple. This social investment will be directed by company organizations and independent foundations that have operated in Dole’s Latin American production areas for decades and will be invested in the communities according to local needs.
  • Dole produce is grown in areas where water is becoming increasingly scarce, and Dole is committed to reduce water usage while improving water quality in its operations.
  • Dole will continue to take action to promote healthy eating and nutrition education, with a special focus on youth. At its core, this is a promise to support people living longer and healthier lives.
  • Dole recognizes that climate change is real and that the food and agriculture industries have a role to play in mitigating its effects. Dole will focus on decreasing its carbon footprint by ensuring new vessels include efficiency upgrades and working towards achieving net zero carbon emissions at farm level by 2030.

Other important sustainability targets include ensuring all packaging materials used in Dole’s banana and pineapple businesses are either recyclable or compostable by 2025, and introducing blockchain or similar technology in all operations to bring about a step-change in food safety and transparency.

Reporting on the impacts of Dole’s responsibility and sustainability goals is also of critical importance.

“This report and our goals are a new milestone in our sustainability pursuit, and farming is at the heart of that transformation. As farmers, we are facing the reality of climate change and are joining all other concerned people and businesses willing to tackle this challenge in our supply chain,” said Xavier Roussel, Vice President of Sustainability. “We will build on our learning—both in precision farming and organic agriculture—to deliver on our commitments in alliance with our business partners and other stakeholders. As an employer we will continue to make a difference in the lives of our employees and local communities and make a positive impact both within our farm borders and beyond.”

Added Roussel, “Dole is absolutely committed to being part of the community of concerned citizens taking on the sustainability challenge.”

To view all Dole’s achievements and goals click the link to the 2020 Corporate Responsibility & Sustainability Report click here.

About Dole Food Company

Dole Food Company, Inc., is one of the world’s largest producers and marketers of high-quality fresh fruit and fresh vegetables. Dole is an industry leader in many of the products it sells, as well as in nutrition education. For more information, please visit www.dole.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

US Contact: William Goldfield
818-874-4647
william.goldfield@dole.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 13:30:00 EET | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations for treatment-resistant depression (TRD) from 10:00-11:30 am ET on January 7th. “PTSD is one of the most challenging mental health conditions, with approximately 13 million adults in the U.S. living with persistent symptoms and limited treatment options,” said Dr. Guy Goodwin, Chief Medical Officer at Compass Pathways. “We are pleased to advance our clinical development - the unmet need is profound, and it demands bold innovation. We believe COMP360 has the potential to tra

Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 12:07:00 EET | Press release

Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,

ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 11:00:00 EET | Press release

CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including

I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 10:00:00 EET | Press release

I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that underpin public safety, mobility and economic activity. Ramudden operates in markets where demand is steady and growing and benefits from deep commerci

RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 10:00:00 EET | Press release

RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye